Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.74 |
| ▸ | GPR4 | P46093 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8127924 | 0.86 | PPARG (0.64) | AGTR1AGTR2GPR4PPARG | |
| SCHEMBL8126181 | 0.84 | AGTR1 (0.53) | AGTR1AGTR2GPR4PPARG | |
| SCHEMBL9563137 | 0.80 | AGTR2 (0.57) | AGTR1AGTR2GPR4 | |
| SCHEMBL8999434 | 0.77 | — | — | |
| SCHEMBL8741166 | 0.77 | AGTR2 (0.61) | AGTR1AGTR2GPR4PPARG | |
| L-158809 SCHEMBL683357 | 0.76 | AGTR2 (0.71) | AGTR1AGTR2GPR4 | |
| SCHEMBL8140704 | 0.76 | GPR4 (0.54) | AGTR1AGTR2GPR4 | |
| L-158809 SCHEMBL7944169 | 0.76 | AGTR2 (0.70) | AGTR1AGTR2GPR4 | |
| SCHEMBL9137156 | 0.75 | GPR4 (0.53) | AGTR1AGTR2GPR4 | |
| SCHEMBL9139089 | 0.75 | GPR4 (0.51) | AGTR1AGTR2GPR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113056465-B | Tetrahydropyrane (THP) -substituted bicyclic pyrimidinedione compounds | 迈奥卡迪亚公司 | 2025-01-28 | — | — | CN | claimed |
| EP-3873904-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2024-07-10 | — | — | EP | claimed |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-10-27 | — | — | US | claimed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | claimed |
| EP-4736855-A2 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616697-B2 | Methods of treatment with myosin modulator | MyoKardia, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4464321-B1 | TETRAHYDROPYRAN (THP)-SUBSTITUTED BICYCLIC-PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MyoKardia, Inc. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250241903-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | MYOKARDIA INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACECUTICALS CORPORATION | 2022-10-20 | — | — | US | disclosed |
| EP-4054588-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114945372-A | Methods of treatment with myosin modulators | 迈奥卡迪亚公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220265629-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE | MyoKardia, Inc. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-08-18 | — | — | US | disclosed |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | MYOKARDIA INC (US) | 2022-04-07 | — | — | US | disclosed |
| CN-114173782-A | Treatment of cardiac contractile dysfunction and heart failure with reduced ejection fraction using the compound (R) -4- (1- ((3- (difluoromethyl) -1-methyl-1H-pyrazol-4-yl) sulfonyl) -1-fluoroethyl) -N- (isoxazol-3-yl) piperidine-1-carboxamide | 迈奥卡迪亚公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022047004-A1 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | MyoKardia, Inc. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282779-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885GPR4 2074/4885 |
| US-20220106314-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885GPR4 2074/4885 |
| US-20220340569-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDROPYRIDO[2,3-D]PYRIMIDINE-2,4-DIONES FOR TREATING CARDIAC DISEASES | DHPS, THPO, TNNI3 | AGTR1 1015/4885AGTR2 868/4885GPR4 2074/4885 |
| US-20220331282-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885AGTR2 5/4885GPR4 842/4885 |
| US-12616697-B2 | Methods of treatment with myosin modulator | MYH2, MYH14, MYH10 | AGTR1 528/4885AGTR2 228/4885GPR4 4166/4885 |
| US-20220257551-A1 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | MME, DNPEP, AGTR1 | AGTR1 3/4885AGTR2 5/4885GPR4 842/4885 |
| US-20220265629-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUOROETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE | FABP3, TNNI3, TNNT2 | AGTR1 116/4885AGTR2 158/4885GPR4 533/4885 |
| US-20250325531-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | FABP3, TNNI3, TNNT2 | AGTR1 173/4885AGTR2 116/4885GPR4 2944/4885 |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | AGTR1 8/4885AGTR2 9/4885GPR4 523/4885 |
| US-20250241903-A1 | TREATMENT OF SYSTOLIC DYSFUNCTION | FABP3, TNNI3, TNNT2 | AGTR1 173/4885AGTR2 116/4885GPR4 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.